Literature DB >> 16193083

Comparative outcome of reduced intensity and myeloablative conditioning regimen in HLA identical sibling allogeneic haematopoietic stem cell transplantation for patients older than 50 years of age with acute myeloblastic leukaemia: a retrospective survey from the Acute Leukemia Working Party (ALWP) of the European group for Blood and Marrow Transplantation (EBMT).

M Aoudjhane1, M Labopin, N C Gorin, A Shimoni, T Ruutu, H-J Kolb, F Frassoni, J M Boiron, J L Yin, J Finke, H Shouten, D Blaise, M Falda, A A Fauser, J Esteve, E Polge, S Slavin, D Niederwieser, A Nagler, V Rocha.   

Abstract

Results of reduced intensity conditioning regimen (RIC) in the HLA identical haematopoietic stem cell transplantation (HSCT) setting have not been compared to those after myeloablative (MA) regimen HSCT in patients with acute myeloblastic leukaemia (AML) over 50 years of age. With this aim, outcomes of 315 RIC were compared with 407 MA HSCT recipients. The majority of RIC was fludarabine-based regimen associated to busulphan (BU) (53%) or low-dose total body irradiation (24%). Multivariate analyses of outcomes were used adjusting for differences between both groups. The median follow-up was 13 months. Cytogenetics, FAB classification, WBC count at diagnosis and status of the disease at transplant were not statistically different between the two groups. However, RIC patients were older, transplanted more recently, and more frequently with peripheral blood allogeneic stem cells as compared to MA recipients. In multivariate analysis, acute GVHD (II-IV) and transplant-related mortality were significantly decreased (P=0.01 and P<10(-4), respectively) and relapse incidence was significantly higher (P=0.003) after RIC transplantation. Leukaemia-free survival was not statistically different between the two groups. These results may set the grounds for prospective trials comparing RIC with other strategies of treatment in elderly AML.

Entities:  

Mesh:

Year:  2005        PMID: 16193083     DOI: 10.1038/sj.leu.2403967

Source DB:  PubMed          Journal:  Leukemia        ISSN: 0887-6924            Impact factor:   11.528


  116 in total

1.  Successful early unmanipulated haploidentical transplantation with reduced-intensity conditioning for primary graft failure after cord blood transplantation in hematologic malignancy patients.

Authors:  B L Tang; X Y Zhu; C C Zheng; H L Liu; L Q Geng; X B Wang; K Y Ding; W Yao; J Tong; K D Song; L Zhang; P Qiang; Z M Sun
Journal:  Bone Marrow Transplant       Date:  2014-11-03       Impact factor: 5.483

2.  Adult dual umbilical cord blood transplantation using myeloablative total body irradiation (1350 cGy) and fludarabine conditioning.

Authors:  Junya Kanda; David A Rizzieri; Cristina Gasparetto; Gwynn D Long; John P Chute; Keith M Sullivan; Ashley Morris; Clayton A Smith; Donna E Hogge; Janet Nitta; Kevin Song; Donna Niedzwiecki; Nelson J Chao; Mitchell E Horwitz
Journal:  Biol Blood Marrow Transplant       Date:  2010-09-22       Impact factor: 5.742

3.  Prognostic factors in patients aged 50 years or older undergoing allogeneic hematopoietic stem cell transplantation for hematologic malignancy.

Authors:  Hirotaka Takasaki; Masatsugu Tanaka; Takayoshi Tachibana; Ayumi Numata; Katsumichi Fujimaki; Rika Sakai; Shin Fujisawa; Naoto Tomita; Hiroyuki Fujita; Atsuo Maruta; Yoshiaki Ishigatsubo; Heiwa Kanamori
Journal:  Int J Hematol       Date:  2012-03       Impact factor: 2.490

4.  Myeloablative vs reduced-intensity conditioning allogeneic hematopoietic cell transplantation for chronic myeloid leukemia.

Authors:  Saurabh Chhabra; Kwang Woo Ahn; Zhen-Huan Hu; Sandeep Jain; Amer Assal; Jan Cerny; Edward A Copelan; Andrew Daly; Zachariah DeFilipp; Shahinaz M Gadalla; Robert Peter Gale; Siddhartha Ganguly; Betty K Hamilton; Gerhard Carl Hildebrandt; Jack W Hsu; Yoshihiro Inamoto; Abraham S Kanate; H Jean Khoury; Hillard M Lazarus; Mark R Litzow; Sunita Nathan; Richard F Olsson; Attaphol Pawarode; Olle Ringden; Jacob M Rowe; Ayman Saad; Bipin N Savani; Harry C Schouten; Sachiko Seo; Nirav N Shah; Melhem Solh; Robert K Stuart; Celalettin Ustun; Ann E Woolfrey; Jean A Yared; Edwin P Alyea; Matt E Kalaycio; Uday Popat; Ronald M Sobecks; Wael Saber
Journal:  Blood Adv       Date:  2018-11-13

5.  Alternative donor transplantation for older patients with acute myeloid leukemia in first complete remission: a center for international blood and marrow transplant research-eurocord analysis.

Authors:  Daniel Weisdorf; Mary Eapen; Annalisa Ruggeri; Mei-Jie Zhang; Xiaobo Zhong; Claudio Brunstein; Celalettin Ustun; Vanderson Rocha; Eliane Gluckman
Journal:  Biol Blood Marrow Transplant       Date:  2014-02-26       Impact factor: 5.742

Review 6.  Transplantation as disease modifying therapy in adults with inherited metabolic disorders.

Authors:  Sandra Sirrs; Fady Hannah-Shmouni; Stephen Nantel; James Neuberger; Eric M Yoshida
Journal:  J Inherit Metab Dis       Date:  2018-02-01       Impact factor: 4.982

Review 7.  Allogeneic hematopoietic cell transplant for acute myeloid leukemia: Current state in 2013 and future directions.

Authors:  Abraham S Kanate; Marcelo C Pasquini; Parameswaran N Hari; Mehdi Hamadani
Journal:  World J Stem Cells       Date:  2014-04-26       Impact factor: 5.326

8.  The effect of donor type on outcomes in adults with acute myeloid leukemia after reduced-intensity hematopoietic peripheral blood cell transplant - a retrospective study.

Authors:  Nahid Rashid; Michael Slade; Ramzi Abboud; Feng Gao; John F DiPersio; Peter Westervelt; Geoffrey Uy; Keith Stockerl-Goldstein; Rizwan Romee; Mark A Schroeder
Journal:  Transpl Int       Date:  2020-06-19       Impact factor: 3.782

9.  Curative potential of allogeneic hematopoietic stem cell transplant in type 1 diabetes.

Authors:  Kristen E McCabe; Allison J Pollock; Jennifer L Rehm; Kenneth B DeSantes
Journal:  Pediatr Diabetes       Date:  2016-08-30       Impact factor: 4.866

10.  Dose intensification of busulfan in the preparative regimen is associated with improved survival: a phase I/II controlled, randomized study.

Authors:  Simrit Parmar; Gabriela Rondon; Marcos de Lima; Peter Thall; Ronald Bassett; Paolo Anderlini; Partow Kebriaei; Issa Khouri; Prasanth Ganesan; Richard Champlin; Sergio Giralt
Journal:  Biol Blood Marrow Transplant       Date:  2012-12-07       Impact factor: 5.742

View more

北京卡尤迪生物科技股份有限公司 © 2022-2023.